## **Amendments to the Claims:**

This listing of claims will replace all prior listings of claims in the application:

## **Listing of Claims:**

- 1. (currently amended) A transgenic knockout mouse whose genome comprises a disruption in <u>each allele of</u> the mouse's endogenous melanopsin gene, wherein the disruption <u>in each allele</u> prevents the expression of a functional melanopsin protein in cells of the mouse <u>and the mouse exhibits an attenuated circadian rhythm phase-shift in response to a light pulse during a dark portion of an environmental dark/light cycle.</u>
  - 2. (cancelled)
  - 3. (cancelled)
- 4. (currently amended) A cell isolated from the transgenic knockout mouse of claim 1, wherein the genome of the cell comprises a disruption in its endogenous melanopsin gene, and wherein the homozygous disruption in each allele prevents the expression of a functional melanopsin protein in said cell.
- 5. (currently amended) A method for identifying a therapeutic agent for modulating circadian rhythm in a mammal, the method comprising:

administering an agent to a transgenic knockout animal mouse of claim 1-whose genome comprises a disruption in its endogenous melanopsin gene, wherein the disruption prevents the expression of a functional melanopsin protein in cells of the animal and the animal comprises a homozygous disruption of the melanopsin gene; and

selecting an agent that modulates the <u>circadian rhythm phase-shift response of the</u> mouse to a light pulse during a dark portion of an environmental dark/light cycle regulation of circadian rhythm in the animal.

Appl. No. 10/637,710 Amdt. dated January 5, 2007 Reply to Office Action of July 5, 2006 **PATENT** 

- 6. (cancelled)
- 7. (original) The method of claim 5, wherein the selecting step comprises selecting an agent that enhances the circadian rhythm phase-shift response to a light pulse during a dark portion of an environmental dark/light cycle.

8.-21. (cancelled)